-
Something wrong with this record ?
Vancomycin and its crystalline degradation products released from bone grafts and different types of bone cement
E. Klapkova, M. Nescakova, P. Melichercik, D. Jahoda, K. Dunovska, J. Cepova, R. Prusa,
Language English Country United States
Document type Journal Article
Grant support
00064203
Ministry of Health, Czech Republic
- MeSH
- Anti-Bacterial Agents analysis metabolism MeSH
- Bone Cements analysis MeSH
- Humans MeSH
- Methicillin-Resistant Staphylococcus aureus drug effects MeSH
- Microbial Sensitivity Tests MeSH
- Bone Transplantation MeSH
- Vancomycin analysis metabolism MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Vancomycin is often used in orthopedic surgery as a local prophylaxis of bacterial infection. The aim of this work was to compare the release of vancomycin and its biologically inactive crystalline degradation products (CDP-1) during in vitro experiments from different types of local antibiotic delivery systems (bone grafts and bone cements). The concentrations of vancomycin and its crystalline degradation products were determined by high-performance liquid chromatography. Each experiment was performed in a phosphate buffer solution over 21 days. Morselized bone grafts, synthetic bone cements Palacos and Copal, and synthetic bone grafts were tested as local carriers of vancomycin. The highest concentration approximately 670 mg/L of vancomycin was released from synthetic bone grafts Actifuse. Even after 21 days, the concentration of vancomycin was still above the minimum inhibitory concentration (MIC). The maximum concentration of vancomycin released in two experiments with human bone grafts exceeded 600 mg/L during the first day and was still above MIC level 21 days later when the experiment was concluded. By comparing the synthetic bone cements Palacos and Copal, Copal had the average maximum concentration of only 32.4 mg/L and Palacos 35.7 mg/L. The concentration of vancomycin fell below the MIC for vancomycin-resistant Staphylococcus aureus (VRSA) on the seventh day with Palacos and the ninth day with Copal. This study showed the insufficient concentration of released vancomycin from synthetic bone cements at the end of the experiment. For improvement of local prophylaxis, it would be beneficial to increase the amount of vancomycin in bone cements.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027178
- 003
- CZ-PrNML
- 005
- 20210105141543.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-019-00752-w $2 doi
- 035 __
- $a (PubMed)31654320
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Klapkova, Eva $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. eva.klapkova@email.cz.
- 245 10
- $a Vancomycin and its crystalline degradation products released from bone grafts and different types of bone cement / $c E. Klapkova, M. Nescakova, P. Melichercik, D. Jahoda, K. Dunovska, J. Cepova, R. Prusa,
- 520 9_
- $a Vancomycin is often used in orthopedic surgery as a local prophylaxis of bacterial infection. The aim of this work was to compare the release of vancomycin and its biologically inactive crystalline degradation products (CDP-1) during in vitro experiments from different types of local antibiotic delivery systems (bone grafts and bone cements). The concentrations of vancomycin and its crystalline degradation products were determined by high-performance liquid chromatography. Each experiment was performed in a phosphate buffer solution over 21 days. Morselized bone grafts, synthetic bone cements Palacos and Copal, and synthetic bone grafts were tested as local carriers of vancomycin. The highest concentration approximately 670 mg/L of vancomycin was released from synthetic bone grafts Actifuse. Even after 21 days, the concentration of vancomycin was still above the minimum inhibitory concentration (MIC). The maximum concentration of vancomycin released in two experiments with human bone grafts exceeded 600 mg/L during the first day and was still above MIC level 21 days later when the experiment was concluded. By comparing the synthetic bone cements Palacos and Copal, Copal had the average maximum concentration of only 32.4 mg/L and Palacos 35.7 mg/L. The concentration of vancomycin fell below the MIC for vancomycin-resistant Staphylococcus aureus (VRSA) on the seventh day with Palacos and the ninth day with Copal. This study showed the insufficient concentration of released vancomycin from synthetic bone cements at the end of the experiment. For improvement of local prophylaxis, it would be beneficial to increase the amount of vancomycin in bone cements.
- 650 _2
- $a antibakteriální látky $x analýza $x metabolismus $7 D000900
- 650 _2
- $a kostní cementy $x analýza $7 D001843
- 650 _2
- $a transplantace kostí $7 D016025
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a methicilin rezistentní Staphylococcus aureus $x účinky léků $7 D055624
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a vankomycin $x analýza $x metabolismus $7 D014640
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nescakova, Monika $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Melichercik, Pavel $u Department of Orthopaedics, Charles University, First Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Jahoda, David $u Department of Orthopaedics, Charles University, First Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Dunovska, Katerina $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Cepova, Jana $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Prusa, Richard $u Department of Medical Chemistry and Clinical Biochemistry, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 65, č. 3 (2020), s. 475-482
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31654320 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210105141539 $b ABA008
- 999 __
- $a ok $b bmc $g 1604158 $s 1117870
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 65 $c 3 $d 475-482 $e 20191025 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- GRA __
- $a 00064203 $p Ministry of Health, Czech Republic
- LZP __
- $a Pubmed-20210105